ALG-094295

ALG-094295 is a potent, orally bioavailable small molecule inhibitor of the PD-1/PD-L1 checkpoint pathway, developed by Aligos Therapeutics. It functions through a distinct mechanism of action compared to traditional antibody therapies; it binds to PD-L1 and induces its dimerization, which leads to the internalization and subsequent degradation of the PD-L1 protein. In preclinical models, ALG-094295 has demonstrated sub-nanomolar potency and tumor growth inhibition equivalent to established monoclonal antibodies like durvalumab. Its oral bioavailability and ability to degrade the target protein potentially offer improved tumor penetration and a more manageable safety profile compared to injectable PD-1/PD-L1 inhibitors.